The market for managing heterozygous familial hypercholesterolemia (HEFH) management is expected to reach a value of US$ 15.11 billion in fiscal year 2023, up from US$ 13.2 billion in 2022. The market is predicted to grow at a steady CAGR of 14.5% from 2023 to 2033, with an estimated value of US$ 58.54 billion by …